SCHEMBL901690

SCHEMBL901690

CNC(=O)c1cnn2c(O)c(Cc3ccccc3F)c(C)nc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.67
ALDH1A1 P00352 6/20 0.67
HPGD P15428 5/20 0.67
HSD17B10 Q99714 4/20 0.67
POLB P06746 4/20 0.58
LMNA P02545 9/20 0.58
KMT2A Q03164 4/20 0.58
TSHR P16473 3/20 0.58
MEN1 O00255 3/20 0.58
NPC1 O15118 1/20 0.58
GLA P06280 1/20 0.58
RAB9A P51151 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
TP53 P04637 9/20 0.56
MAPT P10636 4/20 0.50
NPSR1 Q6W5P4 3/20 0.50
MAPK1 P28482 1/20 0.50
HTT P42858 2/20 0.47
TTR P02766 1/20 0.47
CYP1A2 P05177 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13236239 0.89 LMNA (0.68) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL12156081 0.87 TP53 (0.64) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL902171 0.86 LMNA (0.66) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL902534 0.86 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL902691 0.85 KDM4E (0.56) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL13413801 0.85 LMNA (0.60) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL902688 0.84 KDM4E (0.55) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL902519 0.84 TP53 (0.55) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL902610 0.83 KDM4E (0.84) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL22680740 0.83 KDM4E (0.73) KDM4EALDH1A1HPGDHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US claimed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP claimed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO claimed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 KDM4E 4265/4885ALDH1A1 441/4885HPGD 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.